

1 **Baculovirus-vectored precision delivery of large DNA cargoes in human genomes**

2

3 Francesco Aulicino^{1*}, Martin Pelosse^{1#}, Christine Toelzer¹, Julien Capin¹, Parisa Meysami¹,
4 Mark Simon Dillingham¹, Christiane Schaffitzel¹ and Imre Berger^{1,2*}

5

6 ¹ BrisSynBio Bristol Synthetic Biology Centre, Biomedical Sciences, School of Biochemistry,
7 1 Tankard's Close, University of Bristol, Bristol BS8 1TD, United Kingdom

8 ² Max Planck Bristol Centre for Minimal Biology, School of Chemistry, University of Bristol,
9 Clantock's Close, Bristol BS8 1TS, United Kingdom

10

11

12

13 [#] Current address: Laboratoire Chimie et Biologie des Métaux CEA Grenoble, 17 Avenue des
14 Martyrs 38054 Grenoble CEDEX 09 France

15

16 ^{*} Correspondence to francesco.aulicino@bristol.ac.uk and imre.berger@bristol.ac.uk

17

18 **Abstract:**

19 Precise gene editing and genome engineering by CRISPR technology requires simultaneous
20 delivery of multiple DNA-encoded components into living cells rapidly exceeding the cargo
21 capacity of currently utilized viral vector systems. Here we exploit the unmatched heterologous
22 DNA cargo capacity of baculovirus to resolve this bottleneck. We implement hybrid DNA
23 techniques (MultiMate) for rapid and error-free assembly of currently up to 25 functional DNA
24 modules in a single baculoviral vector enabling CRISPR-based genome engineering. Utilizing
25 homology-independent targeted integration (HITI), we achieve up to 30% correct genome
26 interventions in human cells, including precision docking of large DNA payloads in the *ACTB*
27 locus. We demonstrate baculovirus-vectored delivery of prime-editing toolkits for seamless
28 DNA search-and-replace interventions achieving, with a single vector, highly efficient
29 cleavage-free trinucleotide insertion in the *HEK3* locus without any detectable indels. Our
30 approach thus unlocks a wide range of editing and engineering applications in human cell
31 genomes.

32

33 **Main**

34 CRISPR/Cas represents a game-changing gene editing tool¹. A programmable DNA nuclease
35 (Cas9) is precisely guided to a specific DNA locus by means of a short single guide RNA
36 (sgRNA) to elicit double strand DNA breaks (DSBs) subsequently repaired through non-
37 homologous end-joining (NHEJ) introducing small insertions-deletions (indels), giving rise to
38 frameshift mutations and functional gene knock-outs (KOs)¹. Unpredictable indels that
39 likewise occur are however undesirable in the context of therapeutic gene editing. Precise gene
40 editing in contrast is typically achieved through homology directed repair (HDR) by providing
41 a DNA template flanked by homology arms of variable length^{1,2}, resulting in precise gene
42 correction or knock-in (KIs)¹. HDR activity however is intrinsically low and mostly restricted
43 to S/G2 cell cycle phases³⁻⁵, reducing the efficiency of the desired gene editing outcome.
44 Significant effort is being made to increase the efficacy of CRISPR-HDR by means of small-
45 molecule NHEJ inhibitors⁶, cell cycle stabilised Cas9 variants^{7,8} and other strategies^{9,10},
46 however, gene editing efficiency *in vivo* has remained low.

47 More recently, homology-independent targeted integration (HITI), was shown to
48 efficiently induce base pair precise KIs in both dividing and non-dividing cells¹¹⁻¹³ by
49 exploiting NHEJ and Cas9 cleaved donors, with exciting potential for gene editing applications
50 *in vivo*^{11,14}. Moreover, single base substitutions can also be achieved by using base editors
51 (BEs) involving catalytically impaired Cas9 variants fused to cytosine or adenine deaminase
52 ^{15,16}and, more recently, prime editors (PEs) using Cas9 nickase fused to reverse transcriptase,
53 achieving genomic interventions with little to no indels and reducing the risks associated with
54 DSBs¹⁷. BE, PE and HITI share in common a reliance on multiple functional DNA and protein
55 elements that must be simultaneously delivered into target cells. This limits their applicability,
56 in particular for future *bona fide* therapeutic interventions that necessitate a systemic approach
57 and where co-transfection of plasmids and proteins, and likewise co-infection of viral vectors,

58 will be problematic or unfeasible. In summary, the large DNA cargo capacity required for
59 implementing these next-generation genomic interventions *in vivo* stands at odds with the
60 limited cargo capacity of available technology, including the currently dominating adeno-
61 associated virus (AAVs) and lentivirus (LVs) vector systems¹⁸. In marked contrast, baculoviral
62 vectors (BVs) have a heterologous DNA cargo capacity far exceeding AAV and LV¹⁸⁻²⁰. BVs,
63 suitably pseudotyped to alter host cell tropism, are already widely used to transduce
64 mammalian cells and living organisms¹⁹⁻²². We demonstrated in a proof of concept that BV is
65 suitable for CRISPR-HDR mediated small (~0.7 kb) DNA insertions with low efficacy
66 (~5%)^{19,23}, as would be expected for HDR³⁻⁵.

67 Here we unlock baculovirus as a vector of choice for next-generation genome
68 intervention approaches, fully exploiting its unprecedented DNA cargo capacity and versatility.
69 We implement and deploy state-of-the-art DNA assembly technology (MultiMate) for error-
70 free bottom-up assembly of multifunctional DNA circuitry comprising the DNA cargo to be
71 inserted as well as all the DNA encoding all CRISPR modalities required to achieve highly
72 efficient genome intervention in a baculovirus-vectored approach.

73

74 **Results**

75 We had previously developed methods to rapidly assemble functional DNA elements into
76 multicomponent circuitry in baculoviral vectors²⁴⁻²⁶. Here, we optimized and fine-tuned our
77 approach by incorporating time-tested MultiSite Gateway recombination modalities to
78 assemble with ease currently up to 25 distinct DNA elements of various sizes (**Fig.1a,**
79 **Extended Data Fig.1a-e, Supplementary Methods**), importantly aiming to significantly
80 reduce prokaryotic elements carried over into the baculovirus which can compromise vector
81 integrity during manufacturing²⁷ (**Extended Data Fig.1f**). We validated the MultiMate system
82 by expressing the eight subunits of human chaperonin CCT/TRiC complex²⁸ in insect cells

83 from a BV comprising MultiMate assembled DNA (23 kb) (**Extended Data Fig.1g-j**). We
84 then assessed MultiMate to efficiently deliver large multicomponent DNAs for expression and
85 live cells imaging of up to 7 fluorescently labelled proteins (MultiMate-Rainbow) in human
86 cells (**Fig.1b, Extended Data Fig.2a**). MultiMate assembly yielded remarkably low error rates
87 validating our approach (**Extended Data Fig.2b**). We deployed BVs harbouring 18 and 23.4
88 kb of MultiMate assembled functional DNA to efficiently transduce HEK293T, HeLa, H4 and
89 SH-SY5Y leading to homogeneous expression and correct subcellular localization of all
90 fluorescently labelled proteins (**Fig.1b, Extended Data Fig.2c**). Moreover, we created
91 MultiMate-CellCycle (9.1 kb) as an improved cell cycle tracking tool implementing FUCCI
92 reporters²⁹ as well as H2B-iRFP expression for accurate transduction efficiency monitoring
93 and cell cycle stage assessment (**Fig.2c, Extended Data Fig.2d,e**). MultiMate-CellCycle BVs
94 efficiently transduced HEK293T, HeLa, H4 and SH-SY5Y cells highlighting differences in
95 their respective cell cycle progressions (**Extended Data Fig.2f**) and enabling 12-hrs time lapse
96 imaging on living HeLa cells, allowing cell cycle tracking also during FUCCI-unstained stages
97 (M-G1 transition) (**Fig1.c, Supplementary Video 1**). These results comprehensively validate
98 the MultiMate assembly platform enabling a wide range of baculovirus-vectored applications.
99

100 **Baculovirus-vectored homology independent targeted integration (HITI)**

101 To date, baculovirus-vectored gene editing approaches were confined to CRISPR-HDR of
102 small insert DNAs with low efficacy^{19,22,23}. HITI toolkits using a viral vector required donor
103 and Cas9/sgRNA to be split between two AAVs due to their limited cargo capacity¹¹, restricting
104 successful gene editing to the fraction of co-infected cells. Moreover, manufacturing complete
105 ‘all-in-one’ HITI vectors is not possible when viral packaging is performed in mammalian cells
106 (typically HEK293T for AAV, LV), because simultaneous expression of Cas9 and sgRNA
107 would inevitably excise the HITI donor, fatally compromising virus production. In marked

108 contrast, BVs are manufactured in insect cells, where the mammalian promoters controlling
109 Cas9 and sgRNA expression are silent and all-in-one HITI construct packaging into the BV is
110 thus entirely feasible.

111 To minimise unpredictable indels and maximise correctly-edited alleles, we sought to
112 analyse and compare HDR and HITI-2c¹¹ strategies by targeting the intronic β -actin (*ACTB*)
113 locus, introducing a synthetic C-terminal exon fused to mCherry and a self-cleaving peptide
114 (T2A)³⁰ followed by a puromycin selection cassette (**Fig.2a**). We eliminated any possibility of
115 leaky expression by outfitting our DNAs with the Cas9 inhibitor AcrII4³¹ under control of a
116 dual prokaryotic and baculoviral promoter (J23119-polH). An additional module expressing
117 eGFP under the constitutive CMV promoter was added to track transduction efficiency. Despite
118 comparable transduction of HEK293T cells, Multimate-HITI-2c resulted in a 3- to 4-fold
119 higher percentage of mCherry+ cells compared to Multimate-HDR (**Fig.2b-c, Extended Data**
120 **Fig.3h**). The BV backbone was rapidly diluted as we expected, while mCherry+ cells were
121 stably maintained over time (**Fig.2b-c**) with absolute gene editing efficiencies reaching 5%
122 (HDR) and 20% (HITI-2c) (**Fig.2c**). Notably, when compared to plasmid transfection,
123 baculovirus-vectored delivery increased gene editing efficiency up to 4-fold regardless of the
124 approach (**Extended Data Fig.3a-c**). To confirm correct gene editing, BV transduced cells
125 were selected with puromycin and then expanded in the absence of selective pressure,
126 demonstrating stably maintained mCherry expression in close to all (>98%) cells (**Fig.2d**).
127 Successful editing was confirmed by PCR genotyping (**Extended Data Fig.3e**), the expected
128 mCherry subcellular localization (**Fig.2e, Extended Data Fig.3f**) and the predicted
129 ACTB::mCherry molecular weight (68 kDa) in western blot (**Fig.2f, Extended Data Fig.3g**).
130 MultiMate-HITI-2c ACTB outperformed HDR editing in all BV transduced cell lines
131 (**Extended Data Fig.3h**). For optimal efficacy, we prepared VSV-G pseudotyped BVs¹⁹ and
132 transduced HEK293T, HeLa, H4 and SH-SY5Y at different multiplicities of transduction

133 (MOT) achieving higher transduction (up to 100%) and editing efficiencies (up to 30%)
134 depending on the cell line (**Fig.2h, Extended Data Fig.3i**). To our best knowledge this is the
135 first assembly and delivery platform to enable efficient homology independent targeted
136 integration in mammalian cells using a single all-in-one viral vector.

137

138 **Safe-harbour integration of large DNA payloads**

139 Precision docking of large multicomponent DNA circuitry in mammalian genomes is a
140 prerequisite for *bona fide* genome engineering, but remains an impeding challenge for currently
141 available viral delivery systems which are constrained by their intrinsic packaging limitations
142 (AAV: ~4 kb; LV: ~8 kb)^{18,20}. We assessed the aptitude of our system for precision DNA
143 docking exploiting MultiMate-HITI-2c (**Supplementary Methods**). We used a new Cre
144 insertion site to generate a series of HITI-2c payloads ranging from 4.7 kb to 18 kb with
145 mTagBFP as a transduction efficiency reporter, resulting in all-in-one MultiMate plasmids of
146 up to 30 kb (**Fig.3a**). Transduction with EMBacY BV³² markedly outcompeted plasmid
147 transfection and editing in HEK293T (**Extended Data Fig.4a-d**). Upon puromycin selection,
148 cells remained >98% mCherry+ (**Extended Data Fig.4e**) confirming precise 5'-end
149 integration. We observed silencing of the 3'-end fluorescent marker correlated with cargo size,
150 which we could fully restore by hygromycin selection (**Fig.3b, Extended Data Fig.4f**). We
151 confirmed correct integration by PCR genotyping and Sanger sequencing (**Fig.3c,d**). We
152 deployed MultiMate-HITI-2c 18K-CGH (30 kb) for baculovirus-vectored delivery with VSV-
153 G pseudotyped BV achieving 100% transduction efficiency in both HEK293T and SH-SY5Y
154 giving rise to 20% and 30% absolute genomic insertion efficiency, respectively (**Fig.3e**). Of
155 note, mCherry expression remained constant over time in the absence of any selective pressure
156 while silencing of 3' eGFP expression (**Fig.3f,g**) was again promptly restored by
157 puromycin/hygromycin selection, remaining stable thereafter (**Fig.3h**). Our results

158 demonstrate that safe-harbour integration of extensive DNA payloads with base-pair precision
159 can be achieved with high-efficiency using all-in-one MultiMate-HITI-2c BVs, setting the
160 stage for future large synthetic gene regulatory network engineering in human genomes.

161

162 **Highly efficient baculovirus-vectorized search-and-replace gene editing**

163 Base editors (BEs)^{15,16} and prime editing (PEs)¹⁷ are new additions to the CRISPR toolkit that
164 could potentially correct up to 89% of the human disease-causing mutations in the absence of
165 DNA cleavage¹⁷. PE in particular, can be harnessed to precisely edit genomes with little to no
166 indels production. PE exploits the nickase Cas9-H840A fused to reverse transcriptase from
167 MMLV (PE2) to make a ssDNA copy of the engineered PegRNA at the edited site, allowing
168 for the generation of all possible point mutations, insertions (up to 44 bp) and deletions (up to
169 80 bp) in the absence of DNA cleavage¹⁷. We chose here to insert a CTT trinucleotide in the
170 *HEK3* locus using the prime editing enzyme PE2¹⁷. PE2 coding sequence spans 6.3 kb
171 (excluding promoter) encoding for a 240 kDa protein that previously could be virally delivered
172 only through multiple split-intein lentiviral vectors¹⁷ due to cargo limitation, but is entirely
173 within the packaging size of BV. We therefore assembled MultiMate-PE2 comprising PE2,
174 *HEK3* PegRNA cassette, VSV-G (for pseudotyping), aeBlue chromoprotein³³ (for visual
175 readout of virus titer) and mTagBFP (for transduction tracking) (**Fig. 4. a, Extended Data**
176 **Fig.5a**). MultiMate-PE2 plasmid transfection resulted in 13% CTT insertion in *HEK3* as
177 assessed by Sanger sequencing and deconvolution using ICE³⁴ (**Extended Data Fig.5b,c**).
178 MultiMate-PE2 BVs production could be easily monitored (**Extended Data Fig.5d**) with
179 excellent transduction efficiencies in the cell lines tested (**Fig.4b,d and Extended Data Fig.5e**).
180 Sanger sequencing on *HEK3* locus amplicons from unsorted cells showed correct CTT editing
181 with base-pair precision (**Fig.4c**) with correct editing contributions after deconvolution of 15-
182 45%, depending on the cell line, and undetectable indels (**Fig.4e**). We increased the

183 transduction titer and observed a dose-dependent effect boosting correct editing events (up to
184 45%) again without any indels detected (**Extended Data Fig.5f-i**) unlocking PE to our
185 baculovirus-vectored approach for future, conceivably multiplexed applications including
186 therapeutic interventions.

187

188 **Discussion**

189 The limited packaging capacity of currently dominating viral vectors (AAV, LV) markedly
190 constrains precise genome editing interventions^{18,20}. We demonstrated here the efficacy of our
191 baculovirus-vectored approach to overcome this limitation. We developed a rapid error-free
192 DNA assembly (MultiMate) to facilitate vector construction with a view to improve BV
193 manufacturing. We implemented homology independent targeted integration (HITI) for precise
194 DNA insertion achieving efficient C-terminal tagging in the *ACTB* locus, markedly
195 outcompeting HDR efficiency. Using our approach, we demonstrated precision safe-harbour
196 integration with outstanding efficacy of large multicomponent DNA payloads. There is no
197 indication that we reached the cargo limit of baculovirus-vectored delivery. In fact, given the
198 wide variation in size of naturally occurring baculoviruses³⁵ we expect that delivery of DNA
199 cargos exceeding 100kb will likely be feasible, enabling insertion of entire metabolic pathways
200 and gene regulatory networks in safe-harbour sites or elsewhere in genomes, additionally
201 incorporating DNA insulator elements^{36,37} to support sustained gene expression. Importantly,
202 we demonstrate the utility of our approach for seamless search-and-replace gene editing by
203 implementing recently developed prime editing (PE) technology¹⁷. Particularly PE, is
204 considered safer when compared to HDR or HITI-2c, which both rely on DNA cleavage. Using
205 a single baculovirus vector, we achieved PE-mediated trinucleotide insertion (CTT) in the
206 *HEK3* locus with up to 45% efficiency in the absence of detectable indels. Taken together, our
207 results establish baculovirus as a vector of choice for precision engineering of large DNA

208 cargoes in human genomes, and we anticipate baculovirus-vectored large-scale genome
209 interventions, even combining safe-harbour integration with concomitant, if needed
210 multiplexed, base or prime editing strategies, enabling complex synthetic biology and
211 therapeutic approaches in the future.

212

213 **References**

- 214 1 Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nature*
215 *Protocols* **8**, 2281 (2013).
- 216 2 Shy, B. R., MacDougall, M. S., Clarke, R. & Merrill, B. J. Co-incident insertion enables
217 high efficiency genome engineering in mouse embryonic stem cells. *Nucleic Acids*
218 *Research* **44**, 7997-8010 (2016).
- 219 3 Lieber, M. R. The Mechanism of Double-Strand DNA Break Repair by the
220 Nonhomologous DNA End-Joining Pathway. *Annual Review of Biochemistry* **79**, 181-
221 211 (2010).
- 222 4 Saha, J., Wang, S.-Y. & Davis, A. J. Examining DNA Double-Strand Break Repair in
223 a Cell Cycle-Dependent Manner. *Methods Enzymol* **591**, 97-118 (2017).
- 224 5 Orthwein, A. *et al.* A mechanism for the suppression of homologous recombination in
225 G1 cells. *Nature* **528**, 422-426 (2015).
- 226 6 Hu, Z. *et al.* Ligase IV inhibitor SCR7 enhances gene editing directed by CRISPR-
227 Cas9 and ssODN in human cancer cells. *Cell & Bioscience* **8**, 12 (2018).
- 228 7 Gutschner, T., Haemmerle, M., Genovese, G., Draetta, Giulio F. & Chin, L. Post-
229 translational Regulation of Cas9 during G1 Enhances Homology-Directed Repair. *Cell*
230 *Reports* **14**, 1555-1566 (2016).
- 231 8 Yang, D. *et al.* Enrichment of G2/M cell cycle phase in human pluripotent stem cells
232 enhances HDR-mediated gene repair with customizable endonucleases. *Scientific*
233 *Reports* **6**, 21264 (2016).
- 234 9 Canny, M. D. *et al.* Inhibition of 53BP1 favors homology-dependent DNA repair and
235 increases CRISPR-Cas9 genome-editing efficiency. *Nature Biotechnology* **36**, 95-102
236 (2018).
- 237 10 Haapaniemi, E., Botla, S., Persson, J., Schmierer, B. & Taipale, J. CRISPR-Cas9
238 genome editing induces a p53-mediated DNA damage response. *Nature Medicine* **24**,
239 927-930 (2018).
- 240 11 Suzuki, K. *et al.* In vivo genome editing via CRISPR/Cas9 mediated homology-
241 independent targeted integration. *Nature* **540**, 144 (2016).
- 242 12 Kelly, J. J. *et al.* A Safe Harbor-Targeted CRISPR/Cas9 Homology Independent
243 Targeted Integration (HITI) System for Multi-Modality Reporter Gene-Based Cell
244 Tracking. *bioRxiv*, 2020.2002.2010.942672 (2020).
- 245 13 Artegiani, B. *et al.* Fast and efficient generation of knock-in human organoids using
246 homology-independent CRISPR-Cas9 precision genome editing. *Nature Cell Biology*
247 **22**, 321-331 (2020).
- 248 14 Suzuki, K. & Izpisua Belmonte, J. C. In vivo genome editing via the HITI method as a
249 tool for gene therapy. *J Hum Genet* **63**, 157-164 (2018).

- 250 15 Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable
251 editing of a target base in genomic DNA without double-stranded DNA cleavage.
252 *Nature* **533**, 420-424 (2016).
- 253 16 Gaudelli, N. M. *et al.* Programmable base editing of A•T to G•C in genomic DNA
254 without DNA cleavage. *Nature* **551**, 464-471 (2017).
- 255 17 Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks
256 or donor DNA. *Nature* **576**, 149-157 (2019).
- 257 18 Sung, L.-Y. *et al.* Efficient gene delivery into cell lines and stem cells using
258 baculovirus. *Nature Protocols* **9**, 1882-1899 (2014).
- 259 19 Mansouri, M. *et al.* Highly efficient baculovirus-mediated multigene delivery in
260 primary cells. *Nature Communications* **7**, 11529 (2016).
- 261 20 Kalesnykas, G. *et al.* Comparative Study of Adeno-associated Virus, Adenovirus, Bacu-
262 lovirus and Lentivirus Vectors for Gene Therapy of the Eyes. *Curr Gene Ther* **17**, 235-
263 247 (2017).
- 264 21 Kost, T. A., Condreay, J. P. & Jarvis, D. L. Baculovirus as versatile vectors for protein
265 expression in insect and mammalian cells. *Nat Biotechnol* **23**, 567-575 (2005).
- 266 22 Hindriksen, S. *et al.* Baculoviral delivery of CRISPR/Cas9 facilitates efficient genome
267 editing in human cells. *PLoS One* **12**, e0179514 (2017).
- 268 23 Mansouri, M., Ehsaei, Z., Taylor, V. & Berger, P. Baculovirus-based genome editing
269 in primary cells. *Plasmid* **90**, 5-9 (2017).
- 270 24 Bieniossek, C. *et al.* Automated unrestricted multigene recombineering for multiprotein
271 complex production. *Nat Methods* **6**, 447-450 (2009).
- 272 25 Sari, D. *et al.* The MultiBac Baculovirus/Insect Cell Expression Vector System for
273 Producing Complex Protein Biologics. *Adv Exp Med Biol* **896**, 199-215 (2016).
- 274 26 Nie, Y. *et al.* ACEMBL Tool-Kits for High-Throughput Multigene Delivery and
275 Expression in Prokaryotic and Eukaryotic Hosts. *Adv Exp Med Biol* **896**, 27-42 (2016).
- 276 27 Pijlman, G. P., de Vrij, J., van den End, F. J., Vlak, J. M. & Martens, D. E. Evaluation
277 of baculovirus expression vectors with enhanced stability in continuous cascaded
278 insect-cell bioreactors. *Biotechnol Bioeng* **87**, 743-753 (2004).
- 279 28 Yam, A. Y. *et al.* Defining the TRiC/CCT interactome links chaperonin function to
280 stabilization of newly made proteins with complex topologies. *Nat Struct Mol Biol* **15**,
281 1255-1262 (2008).
- 282 29 Bajar, B. T. *et al.* Fluorescent indicators for simultaneous reporting of all four cell cycle
283 phases. *Nature methods* **13**, 993-996 (2016).
- 284 30 Liu, Z. *et al.* Systematic comparison of 2A peptides for cloning multi-genes in a
285 polycistronic vector. *Scientific Reports* **7**, 2193 (2017).
- 286 31 Rauch, B. J. *et al.* Inhibition of CRISPR-Cas9 with Bacteriophage Proteins. *Cell* **168**,
287 150-158.e110 (2017).
- 288 32 Fitzgerald, D. J. *et al.* Protein complex expression by using multigene baculoviral
289 vectors. *Nat Methods* **3**, 1021-1032 (2006).
- 290 33 Liljeruhm, J. *et al.* Engineering a palette of eukaryotic chromoproteins for bacterial
291 synthetic biology. *Journal of Biological Engineering* **12**, 8 (2018).
- 292 34 Hsiau, T. *et al.* Inference of CRISPR Edits from Sanger Trace Data. *bioRxiv*, 251082
293 (2018).
- 294 35 Vijayachandran, L. S. *et al.* Gene gymnastics: Synthetic biology for baculovirus
295 expression vector system engineering. *Bioengineered* **4**, 279-287 (2013).
- 296 36 Alhaji, S. Y., Ngai, S. C. & Abdullah, S. Silencing of transgene expression in
297 mammalian cells by DNA methylation and histone modifications in gene therapy
298 perspective. *Biotechnology and Genetic Engineering Reviews* **35**, 1-25 (2019).

299 37 Harraghy, N., Gaussin, A. & Mermod, N. Sustained transgene expression using MAR
300 elements. *Curr Gene Ther* **8**, 353-366 (2008).

301
302

303 **Figure Legends**

304 **Figure 1. MultiMate enables rapid modular assembly of multifunctional DNA circuitry**

305 **for efficient baculovirus-vectored delivery in human cells. a**, MultiMate assembly platform

306 in a schematic view. Symbols are listed (left panel). attL/R flanked DNA from ENTR plasmid

307 modules (upper box, dashed) are assembled on MultiBac-DEST (lower box) and further

308 combined by *in vitro* Cre-mediated recombination to generate multicomponent MultiMate

309 plasmids, maximally eliminating prokaryotic backbone DNA sequences. MultiMate plasmids

310 are integrated in BVs customized for efficient delivery in human cells (right panel). **b**,

311 Confocal live cell imaging of H4, HeLa, HEK293T and SH-SY5Y 48 hours after transduction

312 with MultiMate-Rainbow BV (upper panel) evidencing in all cells homogeneous sustained

313 expression and correct subcellular localization of H2B-iRFP (nucleus), GTS-mTagBFP

314 (Golgi), mAG- β -catenin (membrane and adherens junctions), EYFP-Tubulin (microtubules),

315 mTFP1-Actin (cytoskeleton), mito-mCherry (mitochondria) and CyOFP1-ER (endoplasmic

316 reticulum). Scalebar, 20 μ m. **c**, Twelve-hours confocal time-lapse imaging of live HeLa cells

317 transduced with MultiMate-CellCycle BV (snapshots, **Supplementary Video 1**). Transduced

318 cells constitutively express H2B-iRFP for DNA imaging. mAG-hGeminin and mKO2-hCdt1

319 are stabilised in S/G2 and G1 cell cycle stages, respectively. Upper panel shows G1/S

320 transition, lower panel shows a dividing cell (arrows indicate tracked cells). Scalebar, 10 μ m.

321 DNA elements, plasmid topology and cell cycle schematics are illustrated (upper panel).

322

323 **Figure 2. Baculovirus-vectored delivery of complete multicomponent CRISPR/Cas9**

324 **toolkits for homology independent targeted integration (HITI) in human cells. a**, *ACTB*

325 C-terminal tagging strategy: homologous directed repair (HDR) and homology independent

326 targeted integration (HITI-2c) elements within attL1/attR3 sites (triangles) and MultiMate-
327 HITI-2c ACTB all-in-one DNA circuitry comprising Cas9, HITI-2c donor, sgRNA cassette,
328 eGFP reporter. A module encoding AcrII4 Cas9 inhibitor under control of J23119 and polH
329 promoters ensures vector stability. *ACTB* C-terminal exon is replaced with a synthetic exon,
330 tagged with mCherry::T2A::puromycin. **b-c**, HEK293T cells transduced with MultiMate-HDR
331 or MultiMate-HITI-2c BVs in the absence of puromycin selection, at three- and ten-days post-
332 transduction. **b**, Representative FACS plots and **c**, histogram of flow-cytometry data. Mean \pm
333 s.d. of $n = 3$ independent biological replicates. *** $P < 0.001$, Student's t-test. **d-f**, HEK293T
334 transduced with MultiMate HDR or MultiMate HITI-2c BVs after puromycin selection. **d**,
335 Representative flow-cytometry histograms; **e**, Widefield microscopy, Scalebar=20 μm . **f**,
336 Western blot of total protein extracts. Anti- β -actin antibody was used in top panel with anti-
337 TUBULIN as loading control. **g**, Confocal images of HEK293T, HeLa, H4 and SH-SY5Y cells
338 48 hours after transduction with MultiMate-HITI-2c BV. Scalebar is 50 μm . **h**, Histograms of
339 flow-cytometry data of HEK293T, HeLa, H4 and SH-SY5Y 72 hrs after transduction with
340 MultiMate-HITI-2c VSV-G pseudotyped BVs, multiplicity of transduction (MOT) 1 and 10.
341 Transduction efficiency= % of eGFP+ cells; absolute gene editing efficiency = % of Cherry+
342 cells. Mean \pm s.d. of $n=3$ independent biological replicates.

343

344 **Figure 3. Baculovirus-vectored safe-harbour homology-independent integration of large**
345 **DNA cargoes in human genomes. a**, Safe-harbour HITI-2c strategy, HITI-2c payloads within
346 attL1/attR3 sites (triangles) and MultiMate-HITI-2c ACTB all-in-one plasmid carrying Cas9,
347 HITI-2c payload, sgRNA, AcrII4 and mTagBFP reporter. *ACTB* C-terminal exon is replaced
348 with a synthetic exon, tagged with T2A::mCherry::P2A::puromycin (5' integration marker),
349 DNA insert ranging from 4.7 to 18 kb, and distinct 3' integration markers (CMV Hygromycin
350 (CH), CMV eGFP IRES Hygromycin (CGH) or EF1a EYFP-Tubulin IRES Hygromycin

351 (EYH)). **b-c**, HEK293T transduced with the indicated MultiMate-HITI-2c BVs after
352 puromycin and hygromycin selection. **b**, Confocal microscopy. Scalebar, 100 μ m. **c**, PCR
353 genotyping. Oligonucleotide pairs (colour coded arrows) for each PCR are shown, their
354 approximative position is depicted in (a). **d**, Sanger sequencing of 5' and 3' genotyping PCRs
355 (indicated by * in (c)) of HEK293T transduced with MultiMate-HITI-2c 18K-CGH BV. **e**,
356 Transduction efficiency (left histogram) and absolute gene editing efficiency (right histogram)
357 of HEK293T and SH-SY5Y 72 hours after transduction with MultiMate-HITI-2c 18K-CGH
358 VSV-G pseudotyped BV, derived from flow-cytometry data. Mean \pm s.d. of n = 3 independent
359 biological replicates. **f**, Confocal microscopy pictures of HEK293T and SH-SY5Y 8 days after
360 transduction with MultiMate-HITI-2c 18K-CGH VSV-G pseudotyped BVs in the absence of
361 puromycin or hygromycin selection. **g**, Representative flow-cytometry plots of HEK29T at
362 three- or 24-days post transduction with MultiMate-HITI-2c 18K-CGH VSV-G pseudotyped
363 BV. **h**, Representative flow-cytometry plots of HEK29T transduced with MultiMate-HITI-2c
364 18K-CGH VSV-G pseudotyped BV after puromycin (left) and puromycin/hygromycin
365 selection (right).

366

367 **Figure 4. Highly efficient and indels-free prime-editing by using MultiMate all-in-one BV.**

368 **a**, MultiMate-PE2 for CTT insertion in the HEK3 locus in a schematic view. aeBlue is used
369 for tracking viral amplification and VSV-G for pseudotyping BV, respectively. mTagBFP
370 reports on transfection/transduction efficiency in human cells. **b**, Representative flow-
371 cytometry histograms of HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y cells at 24 hours post
372 transduction with MultiMate-PE2 VSV-G pseudotyped BV. **c**, Representative genotype PCR
373 sanger sequencing of unsorted HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y cells at 96
374 hours post transduction with MultiMate-PE2 VSV-G pseudotyped BV and their respective
375 controls (untransduced parental cell lines). **d**, Transduction efficiencies of HeLa, RPE-1

376 hTERT, HEK293T and SH-SY5Y cells at 24 hours post transduction with MultiMate-PE2
377 VSV-G pseudotyped BV. Mean \pm s.d. of n = 3 independent biological replicates. e, Percentage
378 of correct editing (CTT insertion) in HeLa, RPE-1 hTERT, HEK293T and SH-SY5Y at 96
379 hours post transduction. Data are derived from sanger sequencing deconvolution (ICE), no
380 indels were detected in any of the conditions. Mean \pm s.d. of n = 3 independent biological
381 replicates.

382

383 **Methods**

384 **Gibson assembly of DNA elements**

385 An extensive list of constructs maps and assembly strategies is provided in **Supplementary**
386 **Table 1**. ENTR and DEST vectors were generated using Gibson assembly (NEB Builder Hi-
387 Fi DNA assembly #E2621S) following manufacturer's instructions. Fragments were mixed
388 with a backbone to insert ratio of 1:1 (>3 fragments), 1:2 (<2 fragments), 1:5 (fragments <300
389 bp) in 5 μ l total volume and supplemented with 5 μ l 2xNEB Builder Hi-Fi mix followed by
390 incubation at 50°C for 1 hour. 2 μ l of the assembly mix were transformed into homemade
391 electrocompetent Top10 or Pir⁺ *E.Coli*. followed by recovery at 37°C while shaking for 1 hour
392 and plating on LB/agar plates with the appropriate antibiotics. All the precursors vectors
393 generated in this study were assembled using Gibson assembly of synthetic DNA fragments,
394 oligonucleotides, digested vectors or PCRs amplified with Herculase II fusion (Agilent#
395 600675). A portion of pENTR-D-TOPO (Invitrogen) was used as backbone for all the pMMK
396 ENTR vectors. attL/R sites on pMMK ENTR vectors were obtained by overlap extent PCRs
397 of long oligonucleotides. attR1-Ccldb-Chlo-attR2 cassettes for generating pMMACE DEST
398 were PCR amplified from pInducer-20³⁸. pMMDS DEST was generated by replacing the
399 Chloramphenicol cassette with Ori^{ColE1} PCR amplified from pACEMam1¹⁹. H2B-iRFP was
400 PCR amplified from pCAG-H2BtdiRFP-IP³⁹, EYFP-Tubulin and mTFP1-Actin were

401 amplified from 5-colours MultiBac vectors¹⁹. pMDK 7 kb and 12 kb were generated by cloning
402 promoterless and ATG-less portions of SMG1(NM_015092.5) CDS. Mito-mCherry was
403 generated by fusing mCherry from 7TGC⁴⁰ to the COX8 mitochondrial targeting sequence
404 from 5-colours MultiBac vectors¹⁹. CyOFP1⁴¹ fused to the endoplasmic reticulum targeting
405 sequence (ER) was synthesised by Twist Bioscience. mAG β -catenin was obtained through
406 Gibson assembly of PCR amplified mAG from pL-EF1a mAG-hGeminin⁴², and β -catenin from
407 pL-EF1a β -catenin SV40 Puro⁴³. Golgi targeting sequence (GTS) mTaBFP was synthesised by
408 Twist Bioscience. polH or p10 cassettes were amplified from MultiBac vectors^{32,44}, CCT
409 isoforms were PCR amplified from synthetic vectors from GenScript. SpCas9 was PCR
410 amplified from px459¹, sgRNAs cloning was performed by overlap extent PCRs of hU6 and
411 scaffold fragments amplified from px459¹. HDR and HITI-2c templates were amplified by
412 Gibson assembly of genomic DNA fragments, mCherry was amplified from 7TGC⁴⁰, T2A Puro
413 from px459¹. sgRNAs target in the HITI-2c donors were included as overlapping ends between
414 fragments. polH/J23119 AcrII4³¹ was synthesised by Twist Bioscience. In the HITI-2c
415 payloads for safe-harbour integration, mCherry T2A Puro was replaced with T2A mCherry
416 P2A Puro. P2A was generated by overlap extent PCR of long oligonucleotides. The loxP site
417 was PCR amplified from pACEBac1^{32,44}, Hygromycin, IRES and eGFP were PCR-amplified
418 from p1494 vectors⁴⁵. PE2 was obtained by restriction digestion from pCMV PE2¹⁷ and the
419 HEK3 PegRNA was PCR amplified from pU6-Sp-pegRNA-HEK3_CTT_ins¹⁷. aeBlue³³ was
420 synthesised by Twist Bioscience and VSVG-G was amplified from pMD2.G (Didier Trono lab,
421 Addgene plasmid # 12259).

422

423 **LR recombination**

424 LR recombination was carried out using LR Clonase II (Thermo Fisher #11791020) or LR
425 Clonase II plus (Thermo Fisher #12538120). Although LR Clonase II plus is specifically

426 designed for MultiSite Gateway recombination, LR Clonase II worked with comparable
427 efficiency in our hands. LR reactions were carried out following manufacturer's instructions.
428 One DEST and four ENTR vectors were diluted to 20 femtomoles/ μ l each in TE buffer pH 8.0
429 (Thermo Fisher #12090015). 1 ul of each diluted vector was added to a 0.2 ml PCR tube with
430 2 ul LR Clonase II and 3 ul TE buffer, followed by a brief spin and incubation at 25°C for 16
431 hours. The next day the reaction was terminated by addition of 1 ul proteinase K (provided
432 with LR Clonase II enzymes) and incubation at 37°C for 10 minutes. 2-3 ul were transformed
433 into homemade electrocompetent Top10 or Pir⁺ *E.Coli*, followed by 2 hours recovery at 37°C
434 and plating on LB/agar plates with the appropriate antibiotics. LR recombination products were
435 predicted using APE⁴⁶ with custom recombination reactions. To quickly load MultiMate LR
436 reaction prototype in APE, the following code can be copied and used in Tools/Recombination
437 Reaction Editon/New reaction from clipboard:

438 MultiMate LR Reaction for APE:

```
{ApE recombination reaction:} {MultiMate LR Reaction (1-3-4-5-2)} {{{pMMK ENTR 1} {pMMK  
ENTR 2} {pMMK ENTR 3} {pMMK ENTR 4} DEST} {attB1 0 attB3 0 attB4 0 attB5 0 attB2 1}}
```

439
440 When imported as GenBank or Fasta files, the MultiMate LR reaction in APE will
441 automatically recognize pMMK ENTR1-4 vectors and one DEST donors when launched
442 through Tools/Recombination tools. For manual prediction of MultiMate assembly products, a
443 list of the attL/R sequences and their attB products is provided in **Supplementary Table 3**.

444

445 **Cre-mediated recombination of DNA elements**

446 One acceptor and one or multiple donor vectors were assembled using Cre-mediated
447 recombination as previously described^{26,32,47}. One acceptor and one or more donors were mixed
448 with a ratio of 1:1.1 in distilled H₂O with 0.5 ul (7.5 U) of CRE recombinase (NEB # M0298M)
449 and 1 ul Cre buffer (provided with CRE recombinase) to a final volume of 10 ul in distilled

450 H₂O. 500-1000 ng of total DNA were used for each reaction. Cre-reactions were incubated for
451 1 hour at 37°C, followed by heat inactivation at 70°C for 10 minutes. 2-3 ul were transformed
452 into homemade electrocompetent Top10 *E.Coli*, followed by 2 hours recovery at 37°C and
453 plating on LB/agar plates with the appropriate antibiotics. Cre-recombination products were
454 predicted using Cre-ACEMBLER Vers. 2.0⁴⁷.

455

456 **Cell culture methods**

457 Human cells (HEK293T, HeLa, H4, RPE-1 hTERT and SH-SY5Y) were purchased from
458 ATCC and propagated as adherent cultures in 60 or 100 cm dishes in a humidified incubator
459 (37°C, 5% CO₂). For passaging cells were washed with phosphate saline buffer (DPBS, Gibco
460 # 14190144), detached using 0.25% Trypsin (Thermo Fisher #25200056) followed by a brief
461 incubation at 37°C, centrifuged at 300x RCF and resuspended in fresh media in a new plate at
462 the desired concentration. Suspension cultures of Sf21 insect cells were grown in 125 ml or
463 250 ml polycarbonate Erlenmeyer flasks with vent cap (CORNING, #431143, #431144) at
464 27°C in a shaking incubator. Sf21 were split every 2/3 days and maintained at concentrations
465 between 0.5-2x10⁶ cells/ml. Origin and media formulation recipe for each cell line is reported
466 in **Supplementary Table 4**.

467 For transfection in HEK293T, 2x10⁵ cells/well were seeded in multi-24 wells. Transfections
468 were carried out using Polyfect (QIAGEN #301105), following manufacturer's instructions.
469 Briefly 500 ng of DNA were resuspended in 25 ul of Optimem (Gibco #31985062),
470 supplemented with 5 ul Polyfect and incubated for 15 minutes at room temperature.
471 Transfection mix was resuspended with 100 ul of complete media and added dropwise to each
472 well. Cells were cultured for at least 48 hours before assessing the phenotype (e.g. fluorescence
473 markers expression).

474

475 **Baculovirus vector amplification**

476 Assembled MultiMate vectors were shuttled on baculovirus genomes (bacmids) propagated in
477 *E.Coli* using Tn7 transposition. 200-1000 ng of MultiMate vector were transformed in
478 chemically competent DH10-MultiBacMam-VSV-G¹⁹, DH10-EMBacY³² or commercial
479 DH10Bac (ThermoFisher # 10361012) as previously described³². Bacteria were streaked on
480 LB/Agar plates with Gentamycin, Kanamycin, Tetracyclin, IPTG and Bluo-Gal and incubated
481 for 24-hours for blue-white screening. White colonies were picked and grown overnight in 3
482 ml of LB supplemented with Gentamycin/Kanamycin to extract bacmid DNA through alkaline
483 lysis/ethanol precipitation as previously described^{32,44}.

484 For transfection in insect cells, 0.8-1x10⁶ Sf21 cells/well were seeded on multi-6 well plates in
485 3 ml of Sf-900 II media. 10 ul of purified bacmid were resuspended in 130 ul Sf-900 II media
486 with 10 ul X-treme XP transfection reagent (Roche # 06366236001) and incubated at room
487 temperature for 15 minutes. The entire transfection mix was added dropwise to a single well
488 and cells were incubated at 27°C in a static incubator. V₀ viral stocks were harvested collecting
489 the supernatant of transfected cells 72-96 hours post transfection as previously described^{19,32,47}.
490 1-3 ml of V₀ viral stocks was added to 10 ml of fresh Sf21 cells at 0.8x10⁶ cells/ml. Cells were
491 cultured in 50 ml Falcon tubes while shaking at 27°C and counted every day to monitor cell
492 proliferation and size using Luna cell-counter (LogosBio). Successfully infected cells
493 displayed arrested proliferation and increased average cell size (13-14 µm control, 16-20 µm
494 infected). V₁ viral harvest were collected as previously described 2 days after proliferation
495 arrest (DPA+24)^{19,32,47} by centrifugation at 4500 x rcf. 500 µl/1 ml of V₁ viral stocks was added
496 to 50 ml of fresh Sf21 cells at 0.8x10⁶ cells/ml in 125 ml Erlenmeyer flasks and cells were
497 cultured at 27°C in a shaking incubator. V₂ viral harvests were collected by centrifugation at
498 4500 x rcf, and concentrated 20 times by high-speed centrifugation at 11000 x rcf, followed by

499 resuspension in DPBS supplemented with 3% heat inactivated FBS and 1 %Glycerol for
500 storage at -80°C.

501

502 **Baculovirus vector titration and transduction**

503 For BV expressing fluorescent markers in human cells, titration was performed as previously
504 described⁴⁸. HEK293T were used to determine viral titers. Briefly 5×10^5 cells/well were seeded
505 in multi-48 wells plates in 200 ul of complete media. Concentrated virus was serially diluted
506 in DPBS and 50 μ l were dispensed to each well.

507 Spinoculation (30' at 600 x rcf at 27°C) was used to enhance transduction as previously
508 reported⁴⁸. 24 hours after transduction, cells were analysed using flow-cytometry to determine
509 the percentage of transduced cells. TU/ml values from dilutions giving less than 20%
510 transduction efficiencies were averaged to estimate the titer as previously described⁴⁹ and using

511 **Supplementary Equation 1**. For experiments in which different viral titers were used,
512 multiplicity of transduction (MOT) was calculated as TU/Cn .

513

514 **Confocal and widefield imaging**

515 Confocal images were acquired using a Leica Sp8 equipped with 405, 458, 476, 488, 496, 514,
516 561, 594, 633 nm laser lines and 37°C stage. For time lapse confocal experiments on living
517 cells the stage was supplemented with 5% CO₂. For higher magnification, cells were plated on
518 Lab-Tek borosilicate multi-8 wells (Thermo Fisher # 155411). For experiments in which
519 transduced cells expressed more than 3 different fluorochromes, laser intensity and detection
520 filters were adjusted to reduce spectral overlap using individual fluorescence controls
521 transfections. Widefield and phase contrast images were acquired using a Leica DMI6000
522 equipped with excitation/emission filters optimised for DAPI, GFP, Rhodamine, Texas Red
523 and Far red.

524

525 **Flow cytometry analysis**

526 For flow-cytometry analysis cells were trypsinised and resuspended in complete media
527 supplemented with 3 μ M DRAQ7 (Abcam #ab109202) to counterstain dead cells. Cells were
528 analysed on a BD Fortessa, fluorochromes were detected as follow: eGFP and EYFP (FITC-
529 A), mCherry (PECF594-A), mTagBFP (BV421-A), DRAQ7 (AlexaFluor700-A). SSC-A and
530 FSC-A were used to discriminate single cells and cell populations by size. FlowJo X was used
531 to analyse FCS files. All data represented are percentages of live single cells (DRAQ7-).

532

533 **PCR genotyping, Sanger sequencing and deconvolution**

534 Genomic DNA was extracted with QIAamp DNA Mini Kit (QIAGEN # 51306) following
535 manufacturer's instruction. A list of the predicted gene editing outcome sequences and
536 genotyping oligos is provided in **Supplementary Table 2**. PCRs were performed using
537 KAPA2G Fast Genotyping mix (SigmaAldrich # KK5621) following manufacturer's
538 instruction. Amplicons were run on 0.8% agarose gels, purified using QIAquick Gel Extraction
539 Kit (QIAGEN # 28706) and eluted in distilled ddH₂O. For Sanger sequencing 15 μ l of purified
540 PCR at 5-10 ng/ μ l were mixed with 2 μ l of diluted (10 μ M) sequencing primer and sent to an
541 external sequencing service (Eurofins). Electropherograms (.ab1) from parental and transduced
542 cells were fed into ICE³⁴ from Synthego for sequence deconvolution and indels/knock-in
543 estimation.

544

545 **Western blot analysis**

546 Total protein extracts from HEK293T were obtained by lysing the cells with ice-cold RIPA
547 Buffer (Thermo Fisher # 89901) supplemented with protease inhibitors (Thermo Fisher #
548 78429) for 30' on ice. Insoluble material was pelleted by centrifugation at 16000 x ref at 4°C

549 for 5 minutes. Total protein extracts from insect cells were obtained as previously described³².
550 Proteins concentration were determined using Nanodrop. 10 µg protein/sample were stained
551 with Laemmli buffer, boiled at 95°C for 5 minutes, separated using pre-cast NuPage 4-12%
552 Bis-Tris SDS-Gels (Thermo Fisher # NP0321BOX) and transferred to PVDF membranes using
553 iBlot. Membranes were blocked with 5% non-fat dry milk in T-TBS (50 mM Tris-Cl, pH 7.6,
554 150 mM NaCl, 0.5% Tween) for 1 hour at room temperature. Membranes were incubated with
555 primary antibodies diluted 1:1000 in T-TBS 5% milk overnight at 4°C while rocking, followed
556 by 2 T-TBS washes and incubation with HRP-conjugated secondary antibody diluted 1:2000
557 in T-TBS 5% milk for 1 hour at room temperature. Membranes were washed again with T-TBS
558 and developed using Pierce ECL reagents (Thermo Fisher # 34579) following manufacturer's
559 instructions. Finally, membranes were imaged using MyECL Imager.

560 A list of the primary and secondary antibodies used is provided in **Supplementary Table 5**.

561

562 **CCT/TriC complex purification**

563 Recombinant MultiMate-CCT BV was produced as previously described³² and used to infect
564 Sf21 insect cells at a cell density of 1.0×10^6 /mL in Sf-900 II medium. Cells were harvested 72-
565 96 h after proliferation arrest by centrifugation at 1,000 g for 15 minutes. Cell pellets were
566 resuspended in lysis buffer (50 mM HEPES-NaOH, 200 mM KCl, 10 mM Imidazole, 20 %
567 Glycerol, pH 7.5, supplemented with EDTA-free protease inhibitor (Sigma-Aldrich) and
568 Benzonase (Sigma-Aldrich)) and lysed by short sonication. The lysate was cleared by
569 centrifugation at 18,000 rpm, 4°C, in a F21-8x50y rotor (Thermo Fisher Scientific) for 60
570 minutes. The supernatant was loaded on a TALON column (Generon), equilibrated in TALON
571 A buffer (50 mM HEPES-NaOH, 200 mM KCl, 10 mM Imidazole, 20 % Glycerol, pH 7.5)
572 with a peristaltic pump. The column was washed with ten column volumes (CV) of TALON A
573 buffer before eluting the bound protein complex with a step gradient of TALON B buffer (50

574 mM HEPES-NaOH, 200 mM KCl, 250 mM Imidazole, 20 % Glycerol, pH 7.5). The CCT
575 protein complex was buffer exchanged in Heparin A buffer (50 mM HEPES-NaOH, 100 mM
576 KCl, 10 % Glycerol, pH 7.5) while concentrating. It was then subjected to a Heparin column
577 (GE Healthcare) and eluted with a 1M KCl gradient in Heparin A buffer. Fully formed
578 complexes and disassembled subunits were separated on a Superose 6 10/300 column (GE
579 Healthcare) equilibrated in SEC buffer (20 mM HEPES-NaOH, 200 mM KCl, pH 7.5, 1 mM
580 DTT, 10% Glycerol). Peak fractions were pooled and concentrated and the purity of the CCT
581 complex was analyzed by SDS-PAGE.

582

583 **Electron microscopy**

584 For electron microscopy, copper grids with carbon coating (300 mesh, Electron Microscopy
585 Sciences) were glow discharged for 10 s, and 5 μ L of purified CCT was placed on the grids for
586 1 min. Afterwards the grid was washed for 15 s and floated onto a drop of filtered 3 % uranyl
587 acetate for 1 min. Excess solution on the grids was blotted off using filter paper between each
588 step. Grids were visualized under a FEI Tecnai 20 transmission electron microscope (TEM),
589 and digital micrographs were taken using a FEI Eagle 4Kx4K CCD camera. Particle picking
590 and processing was performed using RELION 2^{50,51}, 2D class averages were generated without
591 applying symmetry or reference models.

592

593 **Data availability statement**

594 All plasmid sequences are provided in **Supplementary Table 1**. MultiMate-CellCycle,
595 MultiMate-Rainbow and MultiMate-HITI-2c ACTB reagents will be made available for
596 distribution by Addgene. All other reagents are available from the authors upon reasonable
597 request.

598

599 **Methods References**

- 600
601 38 Meerbrey, K. L. *et al.* The pINDUCER lentiviral toolkit for inducible RNA interference
602 in vitro and in vivo. *Proceedings of the National Academy of Sciences* **108**, 3665 (2011).
603 39 Miyanari, Y., Ziegler-Birling, C. & Torres-Padilla, M.-E. Live visualization of
604 chromatin dynamics with fluorescent TALEs. *Nature Structural & Molecular Biology*
605 **20**, 1321-1324 (2013).
606 40 Fuerer, C. & Nusse, R. Lentiviral Vectors to Probe and Manipulate the Wnt Signaling
607 Pathway. *PLOS ONE* **5**, e9370 (2010).
608 41 Chu, J. *et al.* A bright cyan-excitable orange fluorescent protein facilitates dual-
609 emission microscopy and enhances bioluminescence imaging in vivo. *Nature*
610 *Biotechnology* **34**, 760 (2016).
611 42 De Jaime-Soguero, A. *et al.* Wnt/Tcf1 pathway restricts embryonic stem cell cycle
612 through activation of the Ink4/Arf locus. *PLOS Genetics* **13**, e1006682 (2017).
613 43 Aulicino, F. *et al.* Canonical Wnt pathway controls mESCs self-renewal through
614 inhibition of spontaneous differentiation via β -catenin/TCF/LEF functions. *bioRxiv*,
615 661777 (2019).
616 44 Berger, I., Fitzgerald, D. J. & Richmond, T. J. Baculovirus expression system for
617 heterologous multiprotein complexes. *Nat Biotechnol* **22**, 1583-1587 (2004).
618 45 Aulicino, F., Theka, I., Ombrato, L., Lluís, F. & Cosma, M. P. Temporal perturbation
619 of the Wnt signaling pathway in the control of cell reprogramming is modulated by
620 TCF1. *Stem Cell Reports* **2**, 707-720 (2014).
621 46 Davis, M. W. ApE - A plasmid editor <https://jorgensen.biology.utah.edu/wayned/apel/>.
622 47 Becke, C., Haffke, M. & Berger, I. Cre-ACEMBLER Software User Manual. (2012).
623 48 Cheng, T. *et al.* [Improving baculovirus transduction of mammalian cells by
624 spinoculation]. *Sheng Wu Gong Cheng Xue Bao* **23**, 546-551 (2007).
625 49 Lo, W.-H., Chen, C.-Y., Yeh, C.-N., Lin, C.-Y. & Hu, Y.-C. Rapid baculovirus titration
626 based on regulatable green fluorescent protein expression in mammalian cells. *Enzyme*
627 *and Microbial Technology* **48**, 13-18 (2011).
628 50 Kimanius, D., Forsberg, B. O., Scheres, S. H. & Lindahl, E. Accelerated cryo-EM
629 structure determination with parallelisation using GPUs in RELION-2. *Elife* **5** (2016).
630 51 Scheres, S. H. W. RELION: Implementation of a Bayesian approach to cryo-EM
631 structure determination. *Journal of Structural Biology* **180**, 519-530 (2012).
632

633

634

635 **Acknowledgement**

636 We thank all members of the Berger, Schaffitzel and Dillingham teams and our academic and
637 industrial collaborators for their contributions. We thank Daniel Fitzgerald (Geneva Biotech)
638 for helpful discussions. We acknowledge generous support from GE Healthcare through a
639 Discovery Research Grant (to I.B.), from BrisSynBio, a BBSRC/EPSRC Research Centre for
640 synthetic biology at the University of Bristol (BB/L01386X/1), and from the Max Planck

641 Bristol Centre for Minimal Biology. I.B. is Investigator of the European Research Council
642 (ERC Advanced Grant DNA-DOCK, Project Nr. 834631).

643

644 **Author contributions**

645 I.B. and F.A. conceived and designed the study with input from C.S. and M.S.D.. F.A.
646 performed experiments and analysed results. F.A. and M.P. designed, implemented and
647 validated DNA assembly protocols. C.T. performed protein purification and EM. J.C and P.M.
648 produced and provided reagents. M.S.D., C.S. and I.B. supervised and guided the research.
649 F.A. and I.B. wrote the manuscript with input from all authors.

650

651 **Competing interest statement**

652 I.B. declares shareholding in Geneva Biotech Sàrl and is inventor on patents and patent
653 applications covering DNA methods and baculovirus reagents licensed to Geneva Biotech Sàrl.

654

655 **Additional Information**

656 Supplementary Information contains: Supplementary Methods detailing MultiMate DNA
657 assembly and MultiMate-HITI-2c safe harbour assembly; Supplementary Tables providing
658 sequences, gene editing outcomes and genotyping oligonucleotides sequences, cell lines and
659 antibodies; Supplementary Equation and Supplementary Video.

660

661 **Extended Data Figure Legends**

662 **Extended Data Figure 1. MultiMate assembly protocol and validation. a**, DNA elements
663 are pasted into four distinct ENTR plasmid modules in between attL/R recombination sites
664 (coloured triangles). **b**, One DEST module and four ENTR modules are assembled by LR
665 recombination *in vitro*. DEST plasmids are adapted from MultiBac Acceptor/Donor suite^{25,32}.

666 In pMMACE DEST, the homing cassette is attR1-Ccldb-Chlo^R-attR2, in pMMDS DEST attR1-
667 Ccldb-Ori^{ColE1}-attR2. **c**, After LR reaction, pMMACE DEST and pMMDS DEST are fused by
668 Cre-recombination. **d**, MultiBac donor plasmids and pMMD DEST vectors can be iteratively
669 added by Cre recombination, barcoded by resistance makers²⁶. **e**, MultiMate plasmid is shuttled
670 into the MultiBac BV by Tn7-mediated recombination in *E. Coli*. MultiMate and MultiBac
671 BVs can be further functionalised by *in vitro* Cre-mediated recombination (d-e). **f**, Plasmid
672 size, number of modules and cargo to prokaryotic backbone DNA ratio (green and grey bars,
673 respectively) for hypothetical 1.5 kb expression cassettes. **g**, Assembly strategy for MultiMate
674 plasmid encoding chaperonin CCTs. CCT subunits were pasted into pMMK ENTR plasmid
675 modules comprising baculoviral promoters (polH, p10), assembled by LR reaction into
676 pMMACE DEST and pMMDS DEST, fused by Cre and loaded on EMBacY³² BV. Expression
677 of MultiMate-CCTs with EMBacY in Sf21 insect cells produces complete CCT/TriC
678 chaperonin. **h**, Western blot of infected Sf21 cells, uninfected cells as control (ctr) with CCT
679 subunit specific antibodies. Anti-His was used to detect His-CCT α . **i**, SDS-PAGE analysis of
680 purified CCT/TriC chaperonin complex. **j**, Negative-stain EM (top) and 2D-class averages
681 (bottom) of purified CCT/TriC. Scalebar, 100 nm.

682

683 **Extended Data Figure 2. MultiMate assembly for baculovirus-vectored delivery of large**
684 **multifunctional DNA in human cells.** **a**, MultiMate-Rainbow assembly in a schematic view.
685 Individual modules in pMMACE, pMMDS DEST and pMMK ENTR as shown (upper panel).
686 Two LR reactions resulted in MultiMate-5-colours and pMMDS-2-colours (middle panel),
687 fused by Cre-mediated recombination *in vitro* to produce MultiMate-Rainbow. **b**, Restriction
688 mapping of five clones each of MultiMate-5-colours (left) pMMDS-2-colours (middle) and
689 Cre-recombined MultiMate-Rainbow (right) evidences robust assembly. **c**, Confocal images
690 of HEK293T, HeLa, H4 and SH-SY5Y cells 48 hours after transduction with MultiMate-5-

691 colours VSV-G pseudotyped BV¹⁹. Scalebar, 20 μ m. **d**, Schematic representation of
692 MultiMate-CellCycle assembly. Individual modules were pasted in pMMACE and pMMK
693 ENTR plasmids (upper panel). **e**, Restriction mapping of five clones each after LR
694 recombination. **f**, Confocal microscopy of HEK293T, SH-SY5Y, HeLa and H4 cells at 48
695 hours after transduction with MutiMate-CellCycle VSV-G pseudotyped BV. Scalebar, 100 μ m.
696

697 **Extended Data Figure 3. Baculovirus-vectored delivery of complete multicomponent**
698 **CRISPR/Cas9 toolkits for homology independent targeted integration (HITI) in human**
699 **cells, continued. a-c**, HEK293T cells transfected with MultiMate-HDR or HITI-2c all-in-one
700 plasmids in the absence of puromycin selection at three- or 14-days post transfection. **a**,
701 representative flow-cytometry plots; **b**, Histograms of absolute (left) and relative (right) gene
702 editing efficiencies. Flow-cytometry data of n = 3 independent biological replicates.
703 ***P<0.001, Student's t-test. Relative gene editing efficiency is calculated as the % of
704 mCherry+ cells over the % of eGFP+ cells. **c**, Confocal microscopy of HEK293T at two-days
705 post transfection with MultiMate-HDR or MultiMate-HITI-2c plasmids. Scalebar, 50 μ m. **d**,
706 Representative flow-cytometry histograms of HEK293T transfected with MultiMate-HDR or
707 MultiMate-HITI-2c after puromycin selection. **e**, Genotype PCR of HEK293T transfected
708 (upper panel) or transduced (lower panel) with MultiMate-HDR or MultiMate-HITI-2c after
709 puromycin selection. **f**, Widefield microscopy images of live HEK293T transfected with
710 MultiMate-HDR or MultiMate-HITI-2c plasmids after puromycin selection. Scalebar, 100 μ m.
711 **g**, Western blot of total protein extracts from puromycin selected HEK293T transfected with
712 MultiMate-HDR, MultiMate-HITI-2c and untransfected HEK293T as a control (ctr). Anti- β -
713 actin antibody was used in top panel, with anti-TUBULIN as a loading control. **h**,
714 Representative confocal images of HEK293T, HeLa, H4 and SH-SY5Y human cells 72 hours
715 after transduction with MultiMate-HDR or HITI-2c BV. Scalebar, 50 μ m. **i**, Representative

716 flow-cytometry plots of HEK293T, HeLa, H4 and SH-SY5Y cells at three-days post
717 transduction with MultiMate-HITI-2c BV, untransduced parental cell lines as a control (ctr).

718

719 **Extended Data Figure 4. Baculovirus-vectored safe-harbour homology-independent**
720 **integration of large DNA cargoes in human genomes, continued. a-b**, Delivery efficiencies
721 of indicated MultiMate-HITI-2c plasmids by transfection (a) or low-titer BV transduction (b)
722 in HEK293T at three-days post transfection/transduction. **c-d**, Absolute gene editing
723 efficiencies of HEK293T at three-days post transfection (c) or low-titer BV transduction (d)
724 with the indicated MultiMate-HITI-2c plasmids. Mean \pm s.d. of $n = 3$ independent biological
725 replicates. Dots and triangles represent total MultiMate plasmid and HITI-2c payload DNA
726 sizes, respectively. **e-f**, Representative flow-cytometry histograms of HEK293T transduced
727 with the indicated MultiMate-HITI-2c BVs and selected with puromycin or
728 puromycin/hygromycin for mCherry expression (e) or eGFP/EYFP expression (f).

729

730 **Extended Data Figure 5. Highly efficient and indels-free prime-editing by using**
731 **MultiMate all-in-one BV, continued a**, Restriction mapping of five randomly picked
732 MultiMate-PE2 clones. **b**, Confocal microscopy images of HEK293T two-days after
733 transfection with MultiMate-PE2 plasmid. **c**, Representative genotype PCR Sanger sequencing
734 of HEK293T four-days after transfection with MultiMate-PE2 and relative sequences
735 contribution after Sanger sequencing deconvolution (ICE). Mean \pm s.d. of $n = 3$ independent
736 biological replicates. **d**, Visual summary of BV amplification. V0: widefield images of Sf21
737 cells in 6-well plates after initial transfection with MultiMate-PE2 BV DNA and control cells
738 (untransfected). All transfected cells show VSV-G induced syncytia. V2: aeBlue expression in
739 suspension culture (upper panel) and centrifuged pellets (lower panel) of Sf21 cells during
740 amplification of MultiMate-PE2 BVs. **e**, Confocal microscopy images of HeLa, RPE-1

741 hTERT, HEK293T and SH-SY5Y at 24-hours post transduction with MultiMate-PE2 BV. **f**,
742 Representative flow-cytometry histograms of mTagBFP expression in HEK293T at 24-hours
743 post transduction. Dotted lines represent gating. **g**, Transduction efficiencies of HEK293T at
744 24-hours post-transduction with the indicated dilutions of MultiMate-PE2 BV. Mean \pm s.d. of
745 $n = 5$ independent biological replicates. **h**, Sanger sequencing comparisons of of *HEK3* locus
746 in HEK293T six days after transduction with the indicated amounts of MultiMate-PE2 BV. **i**,
747 Percentage of correct editing (CTT insertion) in HEK293T six days post transduction with the
748 indicated amounts of MultiMate-PE2 BV. Data are derived from Sanger sequencing
749 deconvolution (ICE), no indels were detected in any of the conditions. Mean \pm s.d. of $n = 3$
750 independent biological replicates.














Fig1_AulicinoBerger



ExtDataFig1_AulicinoBerger







Fig2_AulicinoBerger



ExtDataFig3_AulicinoBerger





Fig3_AulicinoBerger



ExtDataFig4_AulicinoBerger





Fig4_AulicinoBerger



ExtDataFig5_AulicinoBerger